893 patents currently held
164 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
153
Ending by 2030
Nov 2026
Next term end
550
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2029 · Medium confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Jun 2031 · High confidence
Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides
US 11,639,395
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2029.
Methods of Treating Cancer Using PD-1 Axis Binding Antagonists and Tigit Inhibitors
US 9,873,740
Cited by 96 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Apoptosis Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
US 8,546,399
Cited by 130 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Aug 2030 · High confidence
The most cited patent in this portfolio, cited by 583 later US patents, top 1% of utility patents granted in 2012 in our data. Protection runs to 2030.
now held by F. Hoffmann-La Roche AG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 14 to 16, 2026 · next Nov 14
- 15 fees due Dec 4 to 30, 2026 · next Dec 4
- 9 fees due Jan 2 to 30, 2027 · next Jan 2
- 14 fees due Feb 6 to 28, 2027 · next Feb 6
- 16 fees due Mar 3 to 29, 2027 · next Mar 3
- 18 fees due Apr 1 to 30, 2027 · next Apr 1
- 9 fees due May 3 to 28, 2027 · next May 3
- 20 fees due Jun 1 to 30, 2027 · next Jun 1
- 14 fees due Jul 2 to 28, 2027 · next Jul 2
- 15 fees due Aug 2 to 27, 2027 · next Aug 2
- 16 fees due Sep 5 to 30, 2027 · next Sep 5
- 20 fees due Oct 2 to 30, 2027 · next Oct 2
- 9 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- Oct 21Assignment recorded on 1 record: Ungewickell, Alexander Joachim Paul and 2 others to Genentech, Inc. Recorded Oct 21, 2026, executed Jan 22, 2021. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76458, frame 980.
- Oct 21Assignment recorded on 1 record: Genentech, Inc. to Genentech, Inc. and 1 other Recorded Oct 21, 2026, executed May 18, 2022. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76459, frame 102.
- 25 of the patents on this record were granted since Aug 16, 2026
- 12 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 550 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides | 12 in force | to Jul 2029 |
| IL-22 Fc FUSION PROTEINS | 8 in force | to Aug 2034 |
| ANTI-CD3 Antibodies and Methods of Use | 7 in force | to Dec 2036 |
| Methods and Compositions Comprising Purified Recombinant Polypeptides | 7 in force | to Nov 2034 |
| ANTI-CD79B Antibodies and Immunoconjugates and Methods of Use | 7 in force | to Jun 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,514,223 | Cross-Screening System and Methods for Detecting a Molecule Having Binding Affinity for a Target Molecule In force · High confidence | In force | High confidence | |
| US 7,763,245 | Methods and Compositions for Targeting Polyubiquitin In force · High confidence | In force | High confidence | |
| US 7,812,133 | ANTI-OX40L Antibodies and Methods Using Same In force · High confidence | In force | High confidence | |
| US 8,906,648 | Recombinant Production of Vascular Endothelial Growth Factor In force · High confidence | In force | High confidence | |
| US 7,476,724 | Humanized Anti-Cmet Antibodies In force · High confidence | In force | High confidence | |
| US 9,186,293 | Vision Measurement and Training System and Method of Operation Thereof In force · High confidence | In force | High confidence | |
| US 10,179,081 | Vision Measurement and Training System and Method of Operation Thereof In force · High confidence | In force | High confidence | |
| US 9,675,707 | ANTI-TAT226 Antibodies and Immunoconjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,450,315 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 9,139,878 | Methods for Diagnosing and Treating Systemic Lupus Erythematosus In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 893: 164 patents in force now held by others · 537 patents ended · 613 applications pending · 1,618 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.